GLP-1 Market
LLY $1421.02 ▲ +0.8% NVO $42.81 ▲ +6.5% PFE $30.41 ▲ +1.4% VKTX $26.39 ▲ +1.2% KLRA $12.34 ▼ -1.9% GPCR $20.09 ▼ -1.3% RHHBY $59.18 ▼ -2.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

MK-4082 Formulation 4

MK-4082 Formulation 4

Company
Merck Sharp & Dohme LLC
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 4, 2026

Trial details
  • Active, not recruiting NCT NCT07748351

    A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)

    Not yet reported Merck Sharp & Dohme LLC 48 participants Est. completion 2026-12-15 2 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: MK-4082 Formulation 4, MK-4082 Formulation 4 (F4)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.